In patients with luminal B (HER–2 negative) breast cancer who underwent neoadjuvant therapy, AR expression level alone was not an influencing factor for prognosis, whereas AR/ER > 1.06 and residual tumor Ki67 > 23% were risk factors for DFS. This evidence concerns the gene MKI67 and breast carcinoma.